What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the pivotal Phase 3 trial (CLARITY-AD) shows a moderate benefit of lecanemab over placebo on key cognitive endpoints, with statistically significant differences reported. However, the absence of active comparator trials limits the strength of the evidence, as the treatment was only compared to placebo, which does not reflect real-world treatment scenarios.
Does the economic case hold at the expected price? — Cost effectiveness
The reported ICERs for lecanemab are significantly above common thresholds, indicating poor cost-effectiveness. The variability in model outputs and the high costs associated with the treatment further complicate its economic justification.
Is there quality-of-life evidence payers weigh? — Quality of life
While the HRQoL outcomes indicate some preservation of quality of life and reduced caregiver burden, the lack of absolute utility values and the reliance on relative changes limit the robustness of the findings. The HTA bodies have raised concerns about the clinical relevance of these improvements.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile shows a notable incidence of ARIA, particularly in ApoE _4 homozygotes, which raises concerns. However, the adverse events are well-documented, and the management strategies are outlined, indicating a generally acceptable safety profile despite the risks.
Was the drug compared against what payers expect? — Comparator Selection
The pivotal trial used placebo as a comparator, which is not ideal for assessing the treatment’s effectiveness against existing therapies. While symptomatic therapies were allowed, the lack of direct comparisons to active treatments limits the evidence’s applicability.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is broadly representative, with stratification by key demographics and ApoE _4 status. However, the exclusion of ApoE _4 homozygotes from the EU indication raises questions about generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The integration of lecanemab into existing care pathways requires significant adjustments, including frequent MRI monitoring and genetic testing. These requirements may disrupt current practices and pose challenges for healthcare providers.
Are the wider system costs understood? — Resource Use and Cost Implications
The treatment’s implementation involves substantial resource use due to the need for diagnostic imaging and monitoring. The economic burden is significant, and the feasibility concerns raised by HTA bodies indicate potential challenges in widespread adoption.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is anchored by a well-conducted Phase 3 RCT, providing high-certainty data. However, methodological limitations noted by HTA bodies, such as missing data and concerns about unblinding, introduce some uncertainty.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness and safety of lecanemab, particularly in real-world settings. The equity and access issues highlighted in the real-world data further complicate the treatment’s broader impact.
